Zobrazeno 1 - 10
of 889
pro vyhledávání: '"FOLFOXIRI"'
Autor:
Tohru Takahashi, Takahiro Ishii, Taku Maejima, Dai Miyazaki, Susumu Fukahori, Hiroaki Kuwahara, Eriko Aimono, Taichi Kimura, Mitsuru Yanai, Masahiro Hagiwara
Publikováno v:
Cancer Reports, Vol 7, Iss 11, Pp n/a-n/a (2024)
ABSTRACT Background Intensified systemic chemotherapy following minimally invasive surgery for patients with unresectable metastatic colorectal cancer is performed to achieve curative resection and improve quality of life. We report a case of initial
Externí odkaz:
https://doaj.org/article/fe4e61307e484647af7153db36170dc9
Publikováno v:
ESMO Gastrointestinal Oncology, Vol 5, Iss , Pp 100087- (2024)
Introduction: Triplet chemotherapy + bevacizumab (TripletBev) demonstrated an overall survival (OS) benefit for patients with newly diagnosed metastatic colorectal cancer in randomized trials. We aimed to evaluate the uptake and estimate the effectiv
Externí odkaz:
https://doaj.org/article/47ebb20610ed445b92ee71476e5881da
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wenwei Yang, Dong Chen, Yaru Niu, Guifu Wu, Zhangkan Huang, Xinyu Bi, Hong Zhao, Xu Che, Yongkun Sun
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeTo explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM).Patients and methodsThis was a dual-center, phase II trial
Externí odkaz:
https://doaj.org/article/a474726aa473498b8d391eb6fa0e5cff
Autor:
Wen Zhang, Haitao Zhou, Jun Jiang, Yuelu Zhu, Shuangmei Zou, Liming Jiang, Yuan Tang, Jianwei Liang, Yongkun Sun, Zhichao Jiang, Wang Qu, Ying Li, Aiping Zhou
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Purpose Chemoradiotherapy (CRT) remains the standard treatment for locally advanced rectal cancer (LARC). This phase 2 clinical trial was designed to evaluate the efficacy and safety of neoadjuvant triplet chemotherapy with mFOLFOXIRI (folin
Externí odkaz:
https://doaj.org/article/75ea248036bf4ce0aa752d7f0bcc0e73
Autor:
Shenglin Li, Long Yuan, Mengying Yue, Yuan Xu, Suwei Liu, Feng Wang, Xiaoqin Liu, Fengyan Wang, Juan Deng, Qiu Sun, Xianwang Liu, Caiqiang Xue, Ting Lu, Wenjuan Zhang, Junlin Zhou
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Purpose Early evaluation of the efficacy of first-line chemotherapy combined with bevacizumab in patients with colorectal cancer liver metastasis (CRLM) remains challenging. This study used 2-month post-chemotherapy spectral computed tomogra
Externí odkaz:
https://doaj.org/article/4da1945126634477be524cd3c82731c8
Autor:
Yi-Hsin Liang, Jin-Tung Liang, Ben-Ren Lin, John Huang, Ji-Shiang Hung, Shuo-Lun Lai, Tzu-Chun Chen, Jia-Huei Tsai, Yung-Ming Cheng, Ting-Han Tsao, Wen-Ling Hsu, Kuo-Hsing Chen, Kun-Huei Yeh
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 10, Pp 2057-2064 (2022)
Background: Ramucirumab is indicated for salvage treatment after failure of first-line treatment for metastatic colorectal cancer (mCRC). However, the application of ramucirumab at later-line treatment in real-world practice has not received much dis
Externí odkaz:
https://doaj.org/article/827a6da68f80450285f215c0d9aebce3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 1, Pp 447-454 (2022)
Colorectal cancer (CRC) in pregnancy is rare and often presents at a late stage due to the masking of signs by pregnancy. A typical chemotherapeutic regimen for stage III and IV CRC comprised 5-Fluorouracil (5-FU) and oxaliplatin. The treatment of CR
Externí odkaz:
https://doaj.org/article/347778a0082c4f86871b338309c5f90f